Jessica J. Kandel to Bevacizumab
This is a "connection" page, showing publications Jessica J. Kandel has written about Bevacizumab.
Connection Strength
0.063
-
Contrast ultrasound imaging for identification of early responder tumor models to anti-angiogenic therapy. Ultrasound Med Biol. 2012 Jun; 38(6):1019-29.
Score: 0.023
-
Monitoring early tumor response to drug therapy with diffuse optical tomography. J Biomed Opt. 2012 Jan; 17(1):016014.
Score: 0.023
-
Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children's Oncology Group Study. J Clin Oncol. 2008 Jan 20; 26(3):399-405.
Score: 0.017